QTERNMET XR
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QTERNMET XR is an extended-release oral tablet approved by the FDA in May 2019 as a small-molecule NDA. The specific indication and mechanism of action are not disclosed in available data, though the brand name suggests a multi-component metabolic therapy. The product is currently in peak lifecycle stage, indicating strong market penetration and established clinical utility.
Peak4.8 years to LOE
Peak lifecycle status suggests mature sales force, stable team size, and focus on market share defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on QTERNMET XR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.